Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
SERENDIP HOLDINGS, 36% Increase in Ordinary Profit, Update Record High for Fourth Consecutive Term
7318 SERENDIP HOLDINGS Co.,Ltd. 【J-GAAP】
Earnings ReportSERENDIP HOLDINGS Co.,Ltd. <7318> [TSE Growth] announced its financial results after the market closed on May 14th (15:30). The consolidated ordinary profit for the fiscal year ended March 2026 increased by 3.3 times that of the previous period to 2.41 billion yen. For the fiscal year ending March 2027, the consolidated ordinary profit is expected to expand to 36.5% to 3.30 billion yen, marking the fourth consecutive term of record-high profits. This will be the fifth consecutive term of revenue and profit growth.
In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit surged 2.6 times that of the same period last year, reaching 0.70 billion yen. The operating profit margin improved from 2.5% in the same period last year to 3.5%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 19,787 | 477 | 595 | 518 | 29.6 | 0 | May 8, 2024 | J-GAAP |
| Mar, 2025 | 25,124 | 734 | 735 | 2,088 | 115.6 | 0 | May 12, 2025 | J-GAAP |
| Mar, 2026 | 51,163 | 2,189 | 2,418 | 4,147 | 227.3 | 0 | May 14, 2026 | J-GAAP |
| YoY | +103.6% | +198.2% | +229.0% | +98.6% | +96.6% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2026 Guidance | 50,000 | 2,250 | 2,180 | 3,900 | 214.5 | 0 | Nov 11, 2025 | J-GAAP |
| Mar, 2026 Results | 51,163 | 2,189 | 2,418 | 4,147 | 227.3 | 0 | May 14, 2026 | J-GAAP |
| Revision Rate | +2.3% | -2.7% | +10.9% | +6.3% | +6.0% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 | 19,290 | 699 | 585 | 3,064 | 168.4 | 0 | Nov 11, 2025 | J-GAAP |
| Apr - Sep, 2026 Guidance | ー | ー | ー | ー | - | 0 | May 14, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2025 | 25,124 | 734 | 735 | 2,088 | 115.6 | 0 | May 12, 2025 | J-GAAP |
| Mar, 2026 | 51,163 | 2,189 | 2,418 | 4,147 | 227.3 | 0 | May 14, 2026 | J-GAAP |
| Mar, 2027 Guidance | 64,000 | 3,500 | 3,300 | 2,200 | 121.0 | 0 | May 14, 2026 | J-GAAP |
| YoY | +25.1% | +59.9% | +36.5% | -46.9% | -46.7% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Mar, 2025 | 9,666 | 246 | 273 | -405 | -22.4 | 2.5 | May 12, 2025 | J-GAAP |
| Apr - Jun, 2025 | 9,345 | 529 | 557 | 357 | 19.8 | 5.7 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 9,945 | 170 | 28 | 2,707 | 148.8 | 1.7 | Nov 11, 2025 | J-GAAP |
| Oct - Dec, 2025 | 16,048 | 941 | 1,125 | 826 | 45.3 | 5.9 | Feb 10, 2026 | J-GAAP |
| Jan - Mar, 2026 | 15,825 | 549 | 708 | 257 | 14.1 | 3.5 | May 14, 2026 | J-GAAP |
| YoY | +63.7% | +123.2% | +159.3% | - | - |
Related Articles
Trial Holdings, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 24%
VALTES HOLDINGS, 3% Increase in Ordinary Profit for The Current Fiscal Year
DLE, Returning to Profitability This Year
Noile-Immune Biotech, Jan-Mar (1Q) Ordinary Profit Loss Narrows
SYNCLAYER, Jan-Mar (1Q) Ordinary Profit Decreases by 26%
Kamigumi, 8% Decrease in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 20 Yen, Plan to Continue the 205 Yen Policy This Fiscal Year as Well
G-FACTORY, Jan-Mar (1Q) Ordinary Profit Loss Narrows
INNOTECH, 27% Increase in Ordinary Profit, Record High for The First Time in Twenty Six Years, Dividend Raised by 5 Yen
ALMEDIO, The Current Fiscal Year's Ordinary Loss to Narrow
General Oyster, Returning to Profitability This Year